Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Malerba

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Pediatric Surgery|February 19, 2008
Captopril reduces the severity of bowel damage in a neonatal rat model of necrotizing enterocolitisAugusto Zani, Simon Eaton, Francesco Fascetti Leon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2010
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx miceAlberto Malerba, Paul S Sharp, Ian R Graham, et al.
Human Gene Therapy|April 2, 2011
Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx miceTaeyoung Koo, Alberto Malerba, Takis Athanasopoulos, et al.
Molecular Therapy. Nucleic Acids|December 20, 2012
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular DystrophyAlberto Malerba, Jagjeet K Kang, Graham McClorey, et al.
Current Gene Therapy|July 11, 2015
Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)Klaudia Kawecka, Michael Theodoulides, Yalin Hasoglu, et al.
Human Molecular Genetics|July 12, 2019
Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1Alberto Malerba, Pierre Klein, Ngoc Lu-Nguyen, et al.
Metabolites|June 27, 2023
Novel Metabolomic Approach for Identifying Pathology-Specific Biomarkers in Rare Diseases: A Case Study in Oculopharyngeal Muscular Dystrophy (OPMD)Pradeep Harish, Alberto Malerba, Rosemarie H M J M Kroon, et al.
The Journal of Surgical Research|June 23, 2007
Murine muscle precursor cells survived and integrated in a cryoinjured gastroesophageal junctionFrancesco Fascetti-Leon, Alberto Malerba, Luisa Boldrin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2018
Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9Taeyoung Koo, Ngoc B Lu-Nguyen, Alberto Malerba, et al.
The American Journal of Pathology|January 12, 2025
Histopathologic Marks of Tongue in a Mouse Model of Oculopharyngeal Muscular Dystrophy Suggest Biomechanical DefectsRebecca Kordikowski Boix, Erik Bos, Milad Shademan, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Pediatric Surgery|February 19, 2008
Captopril reduces the severity of bowel damage in a neonatal rat model of necrotizing enterocolitisAugusto Zani, Simon Eaton, Francesco Fascetti Leon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 25, 2010
Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx miceAlberto Malerba, Paul S Sharp, Ian R Graham, et al.
Human Gene Therapy|April 2, 2011
Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx miceTaeyoung Koo, Alberto Malerba, Takis Athanasopoulos, et al.
Molecular Therapy. Nucleic Acids|December 20, 2012
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular DystrophyAlberto Malerba, Jagjeet K Kang, Graham McClorey, et al.
Current Gene Therapy|July 11, 2015
Adeno-Associated Virus (AAV) Mediated Dystrophin Gene Transfer Studies and Exon Skipping Strategies for Duchenne Muscular Dystrophy (DMD)Klaudia Kawecka, Michael Theodoulides, Yalin Hasoglu, et al.
Human Molecular Genetics|July 12, 2019
Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1Alberto Malerba, Pierre Klein, Ngoc Lu-Nguyen, et al.
Metabolites|June 27, 2023
Novel Metabolomic Approach for Identifying Pathology-Specific Biomarkers in Rare Diseases: A Case Study in Oculopharyngeal Muscular Dystrophy (OPMD)Pradeep Harish, Alberto Malerba, Rosemarie H M J M Kroon, et al.
The Journal of Surgical Research|June 23, 2007
Murine muscle precursor cells survived and integrated in a cryoinjured gastroesophageal junctionFrancesco Fascetti-Leon, Alberto Malerba, Luisa Boldrin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 7, 2018
Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9Taeyoung Koo, Ngoc B Lu-Nguyen, Alberto Malerba, et al.
The American Journal of Pathology|January 12, 2025
Histopathologic Marks of Tongue in a Mouse Model of Oculopharyngeal Muscular Dystrophy Suggest Biomechanical DefectsRebecca Kordikowski Boix, Erik Bos, Milad Shademan, et al.
Pageof 6